The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic
Steatosis: A Prospective Observational Study

Soliman, Hanan; Ziada, Dina Hazem; Hamisa, Manal; Badawi, Rehab; Hawash, Nehad; Salama, Mohamed Abdelbaset

doi:10.2174/1871530321666210125125500

Cited by 8 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10 Treatment with DAAs reduces liver stiffness; however, this is negatively associated with an increase in the severity of fatty liver. 77,78 Co-existing fatty liver is also a risk factor for Kawaguchi T et al P. 8 HCC after cure in patients with HCV infection. 79,80 Furthermore, Peleg et al demonstrated that fatty liver is a major predictor of all-cause mortality in patients who achieve a sustained virological response following DAA treatment, regardless of fibrosis stage.…”

Section: Importance Of Multiple Etiologies Of Liver Disease: Mafld Viral Hepatitis and Alcoholic Intakementioning

confidence: 99%

“…In patients with HCV infection, DAAs are currently the standard of care and achieve high cure rates in real-world settings [ 10 ]. Treatment with DAAs reduces liver stiffness; however, this is negatively associated with an increase in the severity of fatty liver [ 77 , 78 ]. Co-existing fatty liver is also a risk factor for HCC after cure in patients with HCV infection [ 79 , 80 ].…”

Section: Importance Of Multiple Etiologies Of Liver Disease: Mafld Vi...mentioning

confidence: 99%

See 1 more Smart Citation

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

et al. 2022

View full text Add to dashboard Cite

Fatty liver is now a major cause of liver disease in the Asia-Pacific region. Liver diseases in this region have distinctive characteristics. First, fatty liver is frequently observed in lean/normal-weight individuals. However, there is no standard definition of this unique phenotype. Second, fatty liver is often observed in patients with concomitant viral hepatitis. The exclusion of viral hepatitis from non-alcoholic fatty liver disease limits its value and detracts from the investigation and holistic management of coexisting fatty liver in patients with viral hepatitis. Third, fatty liver-associated hepatocellular carcinoma (HCC) is generally categorized as non-B non-C HCC. Fourth, the population is aging rapidly, and it is imperative to develop a practicable, low-intensity exercise program for elderly patients. Fifth, most patients and nonspecialized healthcare professionals still lack an awareness of the significance of fatty liver both in terms of intrahepatic and extrahepatic disease and cancer. Recently, an international expert panel proposed a new definition of fatty liver: metabolic dysfunction-associated fatty liver disease (MAFLD). One feature of MAFLD is that metabolic dysfunction is a prerequisite for diagnosis. Pertinent to regional issues, MAFLD also provides its diagnostic criteria in lean/normal-weight individuals. Furthermore, MAFLD is independent of any concomitant liver disease, including viral hepatitis. Therefore, MAFLD may be a more suitable definition for fatty liver in the Asia-Pacific region. In this review, we introduce the regional characteristics of fatty liver and discuss the advantages of MAFLD for improving clinical practice for liver disease in the region.

show abstract

Section: Importance Of Multiple Etiologies Of Liver Disease: Mafld Viral Hepatitis and Alcoholic Intakementioning

confidence: 99%

Section: Importance Of Multiple Etiologies Of Liver Disease: Mafld Vi...mentioning

confidence: 99%

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

et al. 2022

View full text Add to dashboard Cite

show abstract

“…В научной литературе данные о динамике стеатоза печени после достижения УВО противоречивы. Часть из них демонстрирует уменьшение САР ТМ по данным ТФ, в том числе и у пациентов с ЦП, через 12-24 недели после окончания терапии ПППД [32][33][34][35], другие, наоборот, прогрессию стеатоза печени [36][37][38]. В проведенном исследовании зарегистрирована высокая распространенность стеатоза печени как до начала ПВТ, так и при длительном мониторинге после достижения УВО.…”

Section: Discussionunclassified

Long-Term Monitoring of Liver Fibrosis and Steatosis in Patients with Chronic Hepatitis C after Achieving a Sustained Virologic Response to Antiviral Therapy

Dudina

Bely

Маев

et al. 2023

Rossijskij žurnal gastroènterologii, gepatologii, koloproktolog

View full text Add to dashboard Cite

Aim: to analyze the dynamics of fibrosis and steatosis of the liver according to fibroelastometry in patients with chronic hep-atitis C (CHC) after ≥ 6 months from transient elastometry (TE) achieving a sustained virologic response (SVR) to antiviral therapy.Materials and methods. At baseline, a prospective observational study included 628 CHC patients with known stage of liver fibrosis (F) before AVT, some of whom were phased out due to non-compliance with the inclusion criteria. The final analysis included 297 patients who had transient elastometry (TE) data with CAP™ technology on the severity of liver fibrosis (± steatosis) before treatment and after ≥ 6 months after reaching SVR (67 % – interferonfree regimens of therapy). Median follow-up from the moment SVR was confirmed was 3 years [2; 6].Results. At the end of the study, the average age of patients was 49 ± 12 years, of which 53 % were men. In the long-term period after reaching SVR, regression of liver fibrosis was diagnosed in 80 % of cases (including in patients with cirrhosis), and the progression of fibrosis was in 3 % of patient. At the same time, regression of liver steatosis was detected only in 31 % of the patient, worsening of the results was in 23 % (26 % of them had the appearance of steatosis (S) of the liver of 1–3 degrees in persons with no fatty liver before the start of AVT). In the group of patients with liver steatosis, the proportion of men was significantly higher (p = 0.004). Clinically significant stages of fibrosis F3–F4 were significantly more often recorded in patients with hepatic steatosis, both before treatment (46 % S1–S3 and 22 % S0, p < 0.001) and after ≥ 6 months after reaching SVR (19 % S1–S3 and 9 % S0, p = 0.023).Conclusion. In patients with chronic hepatitis C with SVR achieved in the long term, despite a significant regression of liver fibrosis, a high prevalence of hepatic steatosis remains. The data obtained indicate the feasibility of routine diagnosis of both fibrosis and steatosis of the liver in the management of patients with chronic HCV infection before and after successful antiviral therapy.

show abstract

“…In addition, persistence and even an increase in the degree of steatosis are observed in patients who achieve a Sustained Virologic Response (SVR) after specific treatment with Direct-Acting Antiviral (DAA) drugs one year after treatment ends. 5 , 6 , 7 Interestingly, diabetes mellitus was reported to be a factor that independently affected liver stiffness after DAA treatment despite SVR. 8 The underlying mechanisms involving the presence of steatosis, especially before treatment, can be alcohol consumption, being overweight, obesity, diabetes type 2 mellitus, HCV genotype, Human Immunodeficiency Virus (HIV) coinfection, and genetic polymorphisms in genes, such as Transmembrane six Superfamily member 2 ( TM6SF2 ), Patatin-Like Phospholipase Domain Containing 3 ( PNPLA3 ) and Microsomal Triglyceride Transfer Protein ( MTTP ).…”

Section: Introductionmentioning

confidence: 99%